Johnson & Johnson (NYSE:JNJ) Q1 2024 Earnings Conference Call April 16, 2024 8:30 AM ET
Company Participants
Jessica Moore - VP, IR
Joaquin Duato - Chairman & CEO
Joseph J. Wolk - EVP & CFO
Jennifer L. Taubert - EVP, Worldwide Chairman, Innovative Medicine
Timothy Schmid - EVP, Worldwide Chairman, MedTech
John C. Reed - EVP, Innovative Medicine, R&D, Johnson & Johnson
Conference Call Participants
Terence Flynn - Morgan Stanley
Lawrence Biegelsen - Wells Fargo Securities
Christopher Schott - J.P. Morgan Chase
Joanne Wuensch - Citigroup Inc.
Chris Shibutani - Goldman Sachs
Danielle Antalffy - UBS
Charles Young - Bank of America
Matthew Miksic - Barclays Bank
Vamil Divan - Guggenheim Securities
Operator
Good morning, and welcome to Johnson & Johnson's First Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conference. This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions]. I would now like to turn the conference call over to Johnson & Johnson. You may begin.
Jessica Moore
Hello everyone. This is Jessica Moore, Vice President of Investor Relations for Johnson & Johnson. Welcome to our company's review of the first quarter business results and our full year financial outlook for 2024. A few logistics before we get into the details. As a reminder you can find additional materials including today’s presentation and associated schedules on the Investor Relations section of the Johnson & Johnson website at investor.jnj.com.
Please note that this presentation contains forward-looking statements regarding, among other things, the company's future operating and financial performance, market position and business strategy. You are cautioned not to rely on these forward-looking statements, which are based on the current expectations of future events using the information available as of the date of this recording, and are subject to certain risk and uncertainties that may cause the company's actual results to differ materially from those projected. A description of these risks, uncertainties and other factors can be found in our SEC filings, including our 2023 Form 10-K, which is available at investor.jnj.com and on the SECs website. Additionally, several of the products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. This slide acknowledges those relationships.
Moving to today's agenda I will start by reviewing the first quarter sales and P&L results for the corporation as well as highlights related to our two businesses. Joe Wolk our CFO will then provide additional business and financial commentary before sharing an overview of our cash position, capital allocation priorities, and guidance for 2024. The remaining time will be available for your questions. Joaquin Duato our Chairman and CEO as well as Jennifer Taubert, John Reed, and Tim Schmid, our Innovative Medicine and MedTech leaders will be joining us for Q&A. To ensure we provide enough time to address your questions, we anticipate the webcast will last approximately 60 minutes. Unless otherwise stated the financial results and guidance highlighted today reflect the continuing operations of Johnson & Johnson. Furthermore, the percentages quoted represent operational results and therefore exclude the impact of currency translation.